Lexicon Pharma and Ipsen Biopharmaceuticals announce Health Canada approval of XERMELO®
Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada announced that Health Canada has approved XERMELO® (telotristat ethyl) 250 mg as a first and only orally administered therapy for treatment of refractory carcinoid syndrome diarrhea in combination with somatostatin analog therapy. October 16, 2018